FIELD: medicine, pharmaceutics.
SUBSTANCE: invention discloses an orally applicable pharmaceutical composition. The pharmaceutical composition contains a core containing a controlled-release polymer matrix containing hydroxypropyl cellulose and sodium salt of carboxymethyl cellulose, and phenylephrine or its pharmaceutically acceptable salt, and an erodible layer optionally containing phenylephrine or its pharmaceutically acceptable salt. When a subject intakes the composition, the controlled-release polymer matrix containing said ingredients provides a zero or near-zero order of release of phenylephrine or its pharmaceutically acceptable salt, and at least a portion of phenylephrine is colon absorbed. Besides, the pharmaceutical composition may contain one or more additional therapeutically active agents specified in a group consisting of an antihistamine, an analgesic, an antipyretic and a non-steroidal anti-inflammatory agent.
EFFECT: invention provides better bioavailability of phenylephrine and leads to prolonged plasma concentration of active phenylephrine observed in single bolus doses of the preparation.
